Eiger Biopharmaceuticals LLC is a United States-based commercial-stage biopharmaceutical company. The Company is focused on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. Its HDV platform includes lonafarnib, an oral farnesylation inhibitor that targets a critical host process involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV, Combination Therapy for HDV, and Peginterferon Lambda (lambda) for COVID-19. LNF is an orally bioavailable, farnesylation inhibitor that has completed a Phase 3 clinical trial for HDV infection. LNF has demonstrated dose-dependent activity in reducing HDV viral load both as a monotherapy and in combination with ritonavir (RTV) and/or PEG IFN-alfa-2a. Lambda is a type III, well-tolerated interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Delayed OTC Markets Other stock markets 01:27:07 28/09/24 am AEST			5-day change	1st Jan Change
8.500 ^USD	-.--%		-.--%	-

01/10/24	Eiger BioPharmaceuticals Files for Chapter 11 Bankruptcy as Liquidation Plan Takes Effect	CI
30/09/24	Eiger BioPharmaceuticals, Inc. Went Out of Business	CI

Market Cap	12.59M 10.86M 9.98M 9.4M 17.66M 1.19B 17.81M 118M 46.06M 583M 47.24M 46.23M 2.02B	P/E 2022	-0.51x	P/E 2023	-0.13x
Enterprise Value	27.95M 24.11M 22.17M 20.86M 39.2M 2.64B 39.53M 263M 102M 1.29B 105M 103M 4.48B	EV / Sales 2022	-836,796x	EV / Sales 2023	1,605,487x
Free-Float	86.47%	Yield 2022 *	-	Yield 2023	-

01/10/24	Eiger BioPharmaceuticals Files for Chapter 11 Bankruptcy as Liquidation Plan Takes Effect	CI
30/09/24	Eiger BioPharmaceuticals, Inc. Went Out of Business	CI
05/09/24	Combined Hearing for Disclosure Statement and Plan Approved for Eiger BioPharmaceuticals, Inc.	CI
05/09/24	Fifth Amended Joint Liquidation Plan Filed by Eiger BioPharmaceuticals, Inc.	CI
04/09/24	First Motion for Exclusivity Period Extension Approved For Eiger BioPharmaceuticals, Inc.	CI
03/09/24	Fourth Amended Joint Liquidation Plan Filed by Eiger BioPharmaceuticals, Inc.	CI
03/09/24	Eiger InnoTherapeutics, Inc. acquired Peginterferon Lambda Assets from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $1 million.	CI
03/09/24	Eiger InnoTherapeutics, Inc. acquired Peginterferon Lambda Assets from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $1 million.	CI
03/09/24	Eiger InnoTherapeutics, Inc. completed the acquisition of Lonafarnib Antiviral Asset of Eiger BioPharmaceuticals, Inc. from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $5.2 million.	CI
28/08/24	Third Amended Joint Liquidation Plan & Disclosure Statement Filed by Eiger BioPharmaceuticals, Inc.	CI
21/08/24	Motion for Asset Sale Approved for Eiger BioPharmaceuticals, Inc.	CI
15/08/24	Second Amended Joint Liquidation Plan & Disclosure Statement Filed by Eiger BioPharmaceuticals, Inc.	CI
05/08/24	Motion for Asset Sale Filed by Eiger BioPharmaceuticals, Inc.	CI

30/08/23	Citigroup Adjusts Eiger BioPharmaceuticals Price Target to $3 From $4, Maintains Buy Rating	MT
30/06/23	Baird Adjusts Price Target on Eiger BioPharmaceuticals to $5 From $3, Maintains Outperform Rating	MT
07/09/22	BTIG Adjusts Eiger BioPharmaceuticals' Price Target to $48 from $57, Maintains Buy Rating	MT
11/10/21	EIGER BIOPHARMACEUTICALS : Wedbush Suspended Coverage on Eiger BioPharmaceuticals	MT
11/05/21	EIGER BIOPHARMACEUTICALS : Citigroup Adjusts Price Target on Eiger BioPharmaceuticals to $26 From $23, Maintains Buy Rating	MT

Eiger BioPharmaceuticals Stock

Stocks

EIGR

US28249U2042

Biotechnology & Medical Research

Valuation: Eiger BioPharmaceuticals

Latest news : Eiger BioPharmaceuticals

Analysts' recommendations: Eiger BioPharmaceuticals

Press Releases: Eiger BioPharmaceuticals

News in other languages: Eiger BioPharmaceuticals

Course Extremes

Managers and Directors: Eiger BioPharmaceuticals

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

01/10/24	Eiger BioPharmaceuticals : DEBTOR AFFILIATES PURSUANT TO CHAPTER 11 OF THE BANKRUPTCY CODE Form 8 K	PU
16/07/24	Eiger BioPharmaceuticals : THIS IS NOT A SOLICITATION OF ACCEPTANCE OR REJECTION OF THE PLAN. THE DEBTORS ARE SEEKING APPROVAL OF THE DISCLOSURE STATEMENT ON A CONDITIONAL BASIS, BUT IT HAS NOT YET BEEN APPROVED BY THE BANKRUPTCY COURT Form 8 K	PU
12/07/24	Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist with FDA Breakthrough Therapy Designation	AQ
07/05/24	Sentynl Therapeutics Announces Global Acquisition of Zokinvy for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals	AQ
02/04/24	Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection	AQ

Manager	Title	Age	Since
Christopher Kurtz CTO	Chief Tech/Sci/R&D Officer	59	18/04/2022
Douglas Staut PRN	Corporate Officer/Principal	-	19/04/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
31/10/23	Propel Bio Management LLC	Buy	Company	278,239	0.6281%
31/10/23	Propel Bio Management LLC	Buy	Company	24,332	0.0549%
18/10/23	Propel Bio Management LLC	Other	Company	4,367,100	9.8588%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EIGER BIOPHARMACEUTICALS	-.--%	-.--%	-.--%	-70.51%	12.59M
LONZA GROUP AG	-0.34%	-0.08%	-12.15%	-10.46%	43.44B
REVOLUTION MEDICINES, INC.	+1.46%	+7.41%	+301.43%	+524.18%	33.54B
IQVIA HOLDINGS INC.	-3.91%	-9.90%	+5.52%	-24.10%	28.48B
BEONE MEDICINES AG	+2.56%	+3.33%	+6.39%	+40.38%	29.2B
CELLTRION, INC.	-0.57%	+3.77%	+12.66%	+20.42%	25.34B
ASCENDIS PHARMA A/S	+0.67%	+8.27%	-	-	14.36B
MEDPACE HOLDINGS, INC.	-1.30%	-3.95%	+50.74%	+102.53%	13.05B
EUROFINS SCIENTIFIC SE	+0.54%	-2.27%	+3.93%	+4.80%	12.67B
IONIS PHARMACEUTICALS, INC.	-0.38%	+0.38%	+100.22%	+80.42%	12.28B
Average	-0.13%	+0.72%	+52.08%	+74.19%	21.24B
Weighted average by Cap.	-0.11%	+0.79%	+61.56%	+103.64%

	2022	2023
Net sales	13.48 11.63 10.69 10.07 18.92 1.27K 19.07 126.74 49.34 624.54 50.61 49.53 2.16K	15.77 13.61 12.51 11.78 22.13 1.49K 22.31 148.26 57.72 730.56 59.2 57.93 2.53K
Net income	-96.78M -83.49M -76.76M -72.25M -136M -9.13B -137M -910M -354M -4.48B -363M -355M -15.51B	-74.96M -64.67M -59.46M -55.96M -105M -7.07B -106M -705M -274M -3.47B -281M -275M -12.01B
Net Debt	-63.29M -54.6M -50.2M -47.25M -88.79M -5.97B -89.53M -595M -232M -2.93B -238M -232M -10.14B	15.36M 13.25M 12.18M 11.47M 21.55M 1.45B 21.73M 144M 56.2M 711M 57.65M 56.41M 2.46B

3 years	1.1	29.07
5 years	1.1	300.64
10 years	1.1	618.9